PMID- 30103707
OWN - NLM
STAT- MEDLINE
DCOM- 20181025
LR  - 20190221
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 18
IP  - 1
DP  - 2018 Aug 13
TI  - Survival and prognostic analysis of preoperative inflammatory markers in patients 
      undergoing surgical resection for laryngeal squamous cell carcinoma.
PG  - 816
LID - 10.1186/s12885-018-4730-x [doi]
LID - 816
AB  - BACKGROUND: To estimate the prognostic value of inflammatory markers in patients 
      with laryngeal squamous cell carcinoma (LSCC). METHODS: A total of 361 resected 
      LSCC patients were included. The preoperative and postoperative 
      neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), 
      monocyte-to-lymphocyte ratio (MLR), alkaline phosphatase (ALP) and l actate 
      dehydrogenase (LDH) were assessed. The Kaplan-Meier survival analysis and Cox 
      regression analysis were conducted on overall survival (OS) and progression-free 
      survival (PFS). RESULTS: Both Kaplan-Meier analysis and univariate analysis 
      demonstrated significant prognostic value of preoperative and postoperative NLR, 
      PLR and MLR. However, only preoperative ALP was predictive of OS and PFS, and LDH 
      failed to be predictor of OS and PFS. The multivariate analysis showed that 
      preoperative NLR (OS: HR = 1.64, 95%CI: 1.06-2.54, p = 0.026; PFS: HR = 1.52, 
      95%CI: 1.04-2.23, p = 0.029) and postoperative MLR (OS: HR = 2.02, 95%CI: 
      1.29-3.14, p = 0.002; PFS: HR = 1.57, 95%CI: 1.05-2.34, p = 0.026) were 
      independently related with survival. CONCLUSIONS: The elevated preoperative NLR, 
      PLR, MLR and ALP were significantly associated with worse survival and cancer 
      progression. The preoperative NLR and postoperative MLR might be independent 
      prognostic markers of OS and PFS in LSCC patients undergoing surgical resection.
FAU - Chen, Linyan
AU  - Chen L
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University and Collaborative Innovation Center, No.37, 
      Guoxue Alley, Chengdu, 610041, People's Republic of China.
FAU - Zeng, Hao
AU  - Zeng H
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University and Collaborative Innovation Center, No.37, 
      Guoxue Alley, Chengdu, 610041, People's Republic of China.
FAU - Yang, Jiapeng
AU  - Yang J
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University and Collaborative Innovation Center, No.37, 
      Guoxue Alley, Chengdu, 610041, People's Republic of China.
FAU - Lu, Yuqing
AU  - Lu Y
AD  - The People's Hospital of Hechi, Hechi, Guangxi, People's Republic of China.
FAU - Zhang, Dan
AU  - Zhang D
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University and Collaborative Innovation Center, No.37, 
      Guoxue Alley, Chengdu, 610041, People's Republic of China.
FAU - Wang, Jinggan
AU  - Wang J
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University and Collaborative Innovation Center, No.37, 
      Guoxue Alley, Chengdu, 610041, People's Republic of China.
FAU - Kuang, Chienyun
AU  - Kuang C
AD  - West China School of Stomatology, Sichuan University, Chengdu, People's Republic 
      of China.
FAU - Zhu, Sha
AU  - Zhu S
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University and Collaborative Innovation Center, No.37, 
      Guoxue Alley, Chengdu, 610041, People's Republic of China.
FAU - Wang, Manni
AU  - Wang M
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University and Collaborative Innovation Center, No.37, 
      Guoxue Alley, Chengdu, 610041, People's Republic of China.
FAU - Ma, Xuelei
AU  - Ma X
AD  - Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West 
      China Hospital, Sichuan University and Collaborative Innovation Center, No.37, 
      Guoxue Alley, Chengdu, 610041, People's Republic of China. drmaxuelei@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20180813
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Squamous Cell/*blood/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Head and Neck Neoplasms/*blood/pathology
MH  - Humans
MH  - Inflammation/*blood/pathology
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*blood/pathology
MH  - Lymphocytes/pathology
MH  - Male
MH  - Middle Aged
MH  - Monocytes/pathology
MH  - Neutrophils/pathology
MH  - Platelet Count
MH  - *Prognosis
MH  - Squamous Cell Carcinoma of Head and Neck
PMC - PMC6090788
OTO - NOTNLM
OT  - Laryngeal cancer
OT  - Lymphocyte
OT  - Monocyte
OT  - Neutrophil
OT  - Platelet
OT  - Prognosis
COIS- This study was approved by the institution Ethics Commission of West China 
      Hospital of Sichuan University. The need for consent to participate was waived by 
      Ethics Commission of West China Hospital of Sichuan University. Not applicable. 
      The authors declare that they have no competing interests. Springer Nature 
      remains neutral with regard to jurisdictional claims in published maps and 
      institutional affiliations.
EDAT- 2018/08/15 06:00
MHDA- 2018/10/26 06:00
PMCR- 2018/08/13
CRDT- 2018/08/15 06:00
PHST- 2018/02/20 00:00 [received]
PHST- 2018/08/07 00:00 [accepted]
PHST- 2018/08/15 06:00 [entrez]
PHST- 2018/08/15 06:00 [pubmed]
PHST- 2018/10/26 06:00 [medline]
PHST- 2018/08/13 00:00 [pmc-release]
AID - 10.1186/s12885-018-4730-x [pii]
AID - 4730 [pii]
AID - 10.1186/s12885-018-4730-x [doi]
PST - epublish
SO  - BMC Cancer. 2018 Aug 13;18(1):816. doi: 10.1186/s12885-018-4730-x.